Cipla Limited (CIPLA.BO)
BSE - BSE Real-time price. Currency in INR
Add to watchlist
As of 10:24AM IST. Market open.
| Previous close | 910.50 |
| Open | 910.50 |
| Bid | 899.70 x 0 |
| Ask | 900.00 x 0 |
| Day's range | 898.60 - 914.05 |
| 52-week range | 356.75 - 914.05 |
| Volume | |
| Avg. volume | 204,378 |
| Market cap | 725.689B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 44.13 |
| EPS (TTM) | N/A |
| Earnings date | 06 Aug 2019 - 10 Aug 2019 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Cipla receives final approval for generic version of Novartis Pharmaceuticals Corporation Durezol® (Difluprednate Ophthalmic Emulsion 0.05%)
Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the United States Food and Drug Administration (US FDA).
- PR Newswire
Cipla receives final approval for generic version of Sunovion Pharmaceuticals, Inc.'s Brovana® (Arformoterol Tartrate Inhalation Solution 15 mcg/ 2mL)
Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Arformoterol Tartrate Inhalation Solution 15 mcg / 2 mL from the United States Food and Drug Administration (US FDA).
© 2022 Yahoo. All rights reserved.
